P
5.86
0.33 (5.97%)
Previous Close | 5.53 |
Open | 5.60 |
Volume | 1,057,215 |
Avg. Volume (3M) | 733,592 |
Market Cap | 517,585,120 |
Price / Sales | 5.13 |
Price / Book | 2.73 |
52 Weeks Range | |
Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
Profit Margin | -98.10% |
Operating Margin (TTM) | -85.88% |
Diluted EPS (TTM) | -1.29 |
Quarterly Revenue Growth (YOY) | 5.50% |
Total Debt/Equity (MRQ) | 21.81% |
Current Ratio (MRQ) | 6.91 |
Operating Cash Flow (TTM) | -42.70 M |
Levered Free Cash Flow (TTM) | -23.09 M |
Return on Assets (TTM) | -17.90% |
Return on Equity (TTM) | -51.25% |
Market Trend
Short Term | Medium Term | ||
Industry | Diagnostics & Research (US) | Bearish | Bearish |
Diagnostics & Research (Global) | Bearish | Bearish | |
Stock | Personalis, Inc. | Mixed | Bullish |
AIStockmoo Score
0.8
Analyst Consensus | 1.0 |
Insider Activity | NA |
Price Volatility | -4.5 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 4.0 |
Average | 0.75 |
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
Sector | Healthcare |
Industry | Diagnostics & Research |
Investment Style | Small Value |
% Held by Insiders | 31.49% |
% Held by Institutions | 46.22% |
Ownership
Name | Date | Shares Held |
---|---|---|
Blue Water Life Science Advisors, Lp | 31 Dec 2024 | 1,132,900 |
52 Weeks Range | ||
Price Target Range | ||
High | 9.00 (HC Wainwright & Co., 53.58%) | Buy |
Median | 8.00 (36.52%) | |
Low | 7.00 (Needham, 19.45%) | Buy |
Average | 8.00 (36.52%) | |
Total | 2 Buy | |
Avg. Price @ Call | 3.94 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 07 May 2025 | 9.00 (53.58%) | Buy | 4.84 |
Needham | 10 Apr 2025 | 7.00 (19.45%) | Buy | 3.03 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |